Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093280 | 1.00 | CES2 (0.53) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL4093278 | 1.00 | CES2 (0.53) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL10399267 | 0.85 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3941071 | 0.85 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3940143 | 0.85 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3944597 | 0.83 | MAOB (0.55) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3944593 | 0.83 | MAOB (0.55) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3940626 | 0.82 | NR4A1 (0.49) | CES2MAOBSRD5A2 | |
| SCHEMBL3939814 | 0.82 | NR4A1 (0.49) | CES2MAOBSRD5A2 | |
| SCHEMBL3940623 | 0.82 | NR4A1 (0.49) | CES2MAOBSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | CES2 3693/4885MAOB 747/4885SRD5A2 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.